The critical role of pharmaceuticals and radiotherapy in lung cancer management cannot be overstated. Despite the well-documented adverse effects of electromagnetic radiation, identifying them can often be a complex task. In a particular case, a male patient aged 58 was diagnosed with stage III squamous cell lung cancer, categorized as cT1aN2M0. His treatment regimen included a combination of biweekly chemotherapy using carboplatin and cisplatin over a six-week period, accompanied by a course of 80 Gy distributed across 30 sessions of thoracic radiotherapy. This was followed by bi-monthly administration of durvalumab over the course of a year.At the conclusion of this durvalumab cycle, the patient complained of back discomfort. The cause was determined by magnetic resonance imaging to be a break caused by compression at the sixth thoracic spine.  Further imaging with a CT scan and chlorine-17 fluorodeoxyglucose PET scan indicated minimal uptake at the seventh thoracic vertebra, suggesting a potential for bone metastasis. However, this was not supported by a laparoscopic biopsy, which found no malignant cells. It was ultimately determined that a radiation-induced fracture was responsible for the symptoms, particularly since the fracture was located within the irradiated area near the seventh cervical vertebra. After the patient underwent surgery, a dual-energy X-ray absorptiometry scan revealed osteopenia in the spine. Initially, pre-surgery imaging had hinted at bone metastases, but ultimately, the postoperative biopsy was instrumental in diagnosing a fracture related to the radiation treatment, ruling out metastasis after the patient had undergone extensive chemotherapy and radiotherapy.